4 mysterious generics??? Alan shows openness....JMO "earnout payment on the 4 mysterious generics they bought in July 2016 that "they can't talk about" (these drugs will be what I anticipate will be the 3rd CMA investigation)"
"These products include Sodium Feredetate oral solution for the treatment of anemia, Trazadone oral solution for the treatment of depression, as well as two additional pipeline products".
On June 1, 2016, the Corporation announced that it had completed the acquisition of the global rights to four generic products through certain of its wholly-owned subsidiaries.
These products include Sodium Feredetate oral solution for the treatment of anemia, Trazadone oral solution for the treatment of depression and antihistamine Alimemazine oral solution and tablets.
The Corporation paid £ 21 for the acquisition with cash on hand. In addition, during the first quarter of 2017, the Corporation made £ 7 million in earn-out payments, as certain performance and supply targets were achieved.